The number of small biopharmaceutical companies doing research into the development of psychedelic compounds for the treatment of mental health problems such as depression and addiction has almost doubled in the last 3 months and now numbers 38. The sector has been analyzed and the editors of munKNEE.com have chosen 15 of them to be constituents in the revised Pure-Play Psychedelic Drug Stocks Index.

Please Note: Every company name below has been hyperlinked to its corporate web site and every company trading symbol has been hyperlinked to stock charts, in-depth financial data, and links to other articles on the company to enable the reader to do their due diligence before making a decision to invest in any stock mentioned. Also, keep in mind that some stocks in this sector trade for less than $1/share (i.e. are penny stocks) and may be susceptible to manipulation by unscrupulous speculators. All prices are in USD unless otherwise noted. Go here to convert to another currency.

The 15 stocks in the revised Pure-Play Psychedelic Drug Stocks Index went up 10.9% last week and are now up 18.5% since the beginning of February. 

Below is the 2-week performance of each of the constituents in the index: Any noteworthy developments over the past 2 weeks are also provided:

1. Seelos Therapeutics* (SEEL) +87% to $4.03/share
   • The average consensus analyst price target of $27.27 forecasts a potential upside of 577% based on the current price.
2. Field Trip Health* (FTRPF) +68% to $6.23/share
   • Opened the world’s first research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics in Jamaica as part of its previously announced strategic partnership with the University of West Indies.
3. Numinus Wellness* (LKYSF) +42% to $1.43/share
   • Q1 2021 financials showed that its launching of compassionate access trials, and augmenting its clinical and research activity - two industry firsts - has expanded its industry presence in a meaningful way.
4. Mind Medicine* (MMEDF) +40% to $4.00/share
   • Entered into a  partnership with Swiss startup MindShift Compounds AG to develop and patent next-gen psychedelic compounds with psychedelic or empathogenic properties.
5. Mindset Pharma (CSE:MSET) +31% to C$1.17/share
   • Proof-of-Concept studies in animal models have shown that several of its proprietary, novel, and diverse psychedelic compounds are demonstrating strong potency and efficacy that is superior to psilocybin which represents a significant advancement in Mindset's development of its new psychedelic drug program.
6. Red Light Holland* (TRUFF) +26% to $0.48/share
   • Bruce Linton, now Advisory Board Chairman, is helping TRUFF get positioned to capitalize on what the company sees as a coming global boom in psychedelics. 
7. Champignon Brands (SHRMF) +25% to $0.75/share
   • Under a collaborative research agreement with the University of Miami's Miller School of Medicine, the company is conducting preclinical studies to determine the safety and efficacy of the combination of psilocybin and cannabidiol in treating mild traumatic brain injury or stand-alone PTSD.
8. Revive Therapeutics* (RVVTF) +23% to $0.54/share
   • Under a research agreement with the University of Wisconsin-Madison the company is in the process of developing a novel drug delivery technology for psychedelics and cannabinoids.
9. Novamind (CSE:NM) +15% to C$1.63/share
   • Has made a strategic investment of approximately C$810,000 in Bionomics Limited, a biopharmaceutical company dedicated to developing better treatments for central nervous system disorders.
10. Havn Life*  (HAVLF) +11% to $0.79/share
    • Entered into a partnership with HealthTech Connex Inc., representing the company's first clinical trial execution agreement, and enabling its researchers to draw on the wealth of neuroscientific and technological expertise that HealthTech Connex brings to the table.
11. Compass Pathways* (CMPS) +11% to $48.75/share
    • Has expanded its Discovery Center through collaborations with laboratories at UC San Diego, School of Medicine, and Medical College of Wisconsin, to develop new, optimized psychedelic compounds to address unmet medical need with COMPASS becoming the exclusive licensee for all new compounds generated.
12. Psyence Therapeutics (CSE:PSYG) +2% to C$0.51/share
    • Has entered into a Research Collaboration Agreement with MycoMeditations Inc, the leading global provider of psilocybin-assisted therapeutic retreat experiences, to conduct an observational study of the efficacy of naturally derived psilocybin compared to studies undertaken using synthetically produced molecules.
13. Cybin* (CLXPF) +2% to $1.85/share
    • no news
14. Jaguar Health (JAGX) +1% to $2.86/share
    • no news
15. Mind Cure Health* (CSE:MCUR.wt) just started trading @ C$0.24/warrant
    • Listed its 5-year duration warrants (they expire on February 10, 2026) on the Canadian Securities Exchange with an exercise price of $0.80

* indicates that the stock is also a constituent in the new - and tradable - Horizons Psychedelic Stock Index ETF (NEO: PSYK) which began trading on the Canadian NEO Exchange on January 26th.. It is not a pure-play ETF, however, in that it also includes Johnson & Johnson, AbbVie Inc. and Greenbrook TMS Inc. who are not directing 100% of their efforts into the research and development of psychedelic components for medical applications. The munKNEE Pure-Play Psychedelic Drug Stocks Index, on the other hand, is a pure-play and, as such provides a true picture of the health and trend of this new stock sector. 

As mentioned in the introduction, the psychedelic stocks sector consists of 38 companies of which only 15 are constituents of the munKNEE Pure-Play Psychedelic Drug Stocks Index. For information on the remaining 23 companies please read this previous exclusive post on TalkMarkets. Here are those 23 companies, in no particular order: Mydecine Innovations; PharmaTher; Psyched Wellness; Silo Pharma; TrypTherapeutics; Algeron Pharma; Ehave; Core One Labs; New Wave Holdings; Pure Extracts Technologies; Entheon Biomedical; Nova Mentis Life Science; Aion Therapeutic; Lobe Sciences; Better Plant Sciences; M2Bio Sciences; NeonMind Biosciences; Graph Blockchain; Minerco; Thoughtful Brands; Nutritional High; Codebase and Hollister.